These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 22807471

  • 1. Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).
    Sørensen PS.
    Mult Scler; 2012 Aug; 18(8):1070-2. PubMed ID: 22807471
    [No Abstract] [Full Text] [Related]

  • 2. Deaths and disability from natalizumab are no longer tolerable: Yes.
    Duquette P.
    Mult Scler; 2012 Aug; 18(8):1068-9. PubMed ID: 22807470
    [No Abstract] [Full Text] [Related]

  • 3. Deaths and disability from natalizumab are no longer tolerable: Commentary.
    Hutchinson M.
    Mult Scler; 2012 Aug; 18(8):1073. PubMed ID: 22807472
    [No Abstract] [Full Text] [Related]

  • 4. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
    Damasceno A, von Glehn F, Martinez AR, Longhini AL, Deus-Silva L, Brandão CO, Santos LM, Damasceno BP.
    Mult Scler; 2011 Nov; 17(11):1397-8. PubMed ID: 21900356
    [No Abstract] [Full Text] [Related]

  • 5. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
    Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J.
    Mult Scler; 2012 Jun; 18(6):899-901. PubMed ID: 22183929
    [Abstract] [Full Text] [Related]

  • 6. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.
    Tur C, Tintoré M, Vidal-Jordana A, Castilló J, Galán I, Río J, Arrambide G, Comabella M, Arévalo MJ, Horno R, Vicente MJ, Caminero A, Nos C, Sastre-Garriga J, Montalban X.
    Mult Scler; 2012 Aug; 18(8):1193-6. PubMed ID: 22383232
    [Abstract] [Full Text] [Related]

  • 7. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Aug; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 8. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Olsson T.
    Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
    [Abstract] [Full Text] [Related]

  • 9. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
    Dorsey ER, Thompson JP, Noyes K, Dick AW, Holloway RG, Schwid SR.
    Neurology; 2007 May 01; 68(18):1524-8. PubMed ID: 17470756
    [Abstract] [Full Text] [Related]

  • 10. Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Taieb G, Renard D, Thouvenot E, Servillo G, Castelnovo G.
    J Neurol Sci; 2014 Nov 15; 346(1-2):364-5. PubMed ID: 25241939
    [No Abstract] [Full Text] [Related]

  • 11. Natalizumab risk stratification: role of a two- step anti-JCV antibody assay.
    O'Connor PW.
    Can J Neurol Sci; 2012 Sep 15; 39(5):670-5. PubMed ID: 22931715
    [No Abstract] [Full Text] [Related]

  • 12. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 13. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus.
    Warnke C, Smolianov V, Dehmel T, Andrée M, Hengel H, Zohren F, Arendt G, Wiendl H, Haas R, Hartung HP, Adams O, Kieseier BC.
    Mult Scler; 2011 Feb 17; 17(2):151-6. PubMed ID: 21078695
    [Abstract] [Full Text] [Related]

  • 14. Rituximab in relapsing-remitting multiple sclerosis.
    Schrijver HM.
    N Engl J Med; 2008 Jun 12; 358(24):2645; author reply 2646-7. PubMed ID: 18557177
    [No Abstract] [Full Text] [Related]

  • 15. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.
    Gupta S, Weinstock-Guttman B.
    Expert Opin Biol Ther; 2014 Jan 12; 14(1):115-26. PubMed ID: 24289270
    [Abstract] [Full Text] [Related]

  • 16. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 Jan 12; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 17. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 12; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 18. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
    Pitarokoili K, Gold R.
    Nat Rev Neurol; 2017 Dec 12; 13(12):710-712. PubMed ID: 29146954
    [No Abstract] [Full Text] [Related]

  • 19. Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.
    Serana F, Chiarini M, Sottini A, Bertoli D, Giustini V, Tessitore MV, Caimi L, Capra R, Imberti L.
    J Neuroimmunol; 2014 Dec 15; 277(1-2):6-12. PubMed ID: 25468273
    [Abstract] [Full Text] [Related]

  • 20. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.
    Puig-Casadevall M, Álvarez-Bravo G, Varela AQ, Robles-Cedeño R, Sànchez Cirera L, Miguela A, Laguillo G, Montalban X, Hauser SL, Ramió-Torrentà L.
    Eur J Neurol; 2023 Oct 15; 30(10):3357-3361. PubMed ID: 37485841
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.